The European response to the WHO call to eliminate cervical cancer as a public health problem by Arbyn, Marc et al.
1 
post print  
The European response to the WHO call to eliminate cervical cancer as a 
public health problem 
 
Marc Arbyn1, Murat Gultekin (ESGO)2, Philippe Morice (ESGO)3, Pekka Nieminen4 
(EFC), Maggie Cruickshank (EFC)5, Philip Poortmans (ECCO)6, Daniel Kelly 
(ECCO)7, Mario Poljak (ESCMID) 8, Christine Bergeron9, David Ritchie10, Dietmar 
Schmidt11, Maria Kyrgiou12,13, Ann Van den Bruel14, Laia Bruni15, Partha Basu16, 
Freddie Bray16, Elisabete Weiderpass16 
 
1 Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium; 
2 Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of 
Gynaecological Oncology, Ankara, Turkey;  Chair of Engage (European Network of Gynaecological Cancers 
Advocacy Groups) and Chair of the Prevention Task Force of ESGO (European Society of Gynaecological 
Oncology)  
3 Department of Gynecologic Surgery, Gustave Roussy, Villejuif, France (President of the ESGO); 
4 Department of Obstetrics and Gynaecology, University of Helsinki and University Hospital of Helsinki, 
Finland (President of EFC [European Federation for Colposcopy]); 
5 Aberdeen Centre for Women’s Health Research, University of Aberdeen, Aberdeen UK;  
6 European CanCer Organisation, Brussels, Belgium; 
7 Royal College of Nursing, Chair of Nursing Research, School of Healthcare Sciences, University of Cardiff, 
UK (Co-Chair of ECCO HPV Action Network); 
8 Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia 
(Immediate Past President of ESCMID [European Society of Clinical Microbiology and Infectious Diseases]); 
9 Laboratoire Cerba, Cergy Pontoise France (Past President of the Société Française de Cytologie Clinique 
(SFCC), President of the Société Française de Colposcopie et Pathologie Cervico-Vaginale (SFCPCV), Paris, 
France; 
10 Association of European Cancer Leagues, Brussels, Belgium; 
11 MVZ of Pathology, Cytology and Molecular Diagnostics, Trier, University of Kiel, Germany, President of  the 
International Academy of Pathology; 
12 Department of Gut, Metabolism and Reproduction & Department of Surgery and Cancer, Faculty of 
Medicine, Imperial College London, W12 0NN, UK; 
13 West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust, London, UK; 
14 Academic Centre for General Practice, University of Leuven, Belgium; 
15 Consortium for Biomedical Research in Epidemiology and Public Health and Unit of Infections and Cancer, 
Catalonian Institute of Oncology, Barcelona, Spain; 
16 International Agency for Research on Cancer, Lyon, France. 
 
Corresponding author: Marc Arbyn, Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, J. 
Wytsmanstreet 14, B1050 Brussels, Belgium. Email: marc.arbyn@sciensano.be. 
 
List of abbreviations 
ECCO: European CanCer Organisation 
ECDC: European Centre for Disease Control and Prevention 
ESCMID: European Society of Clinical Microbiology and Infectious Diseases 
EFC: European Federation for Colposcopy 
Engage: European Network of Gynaecological Cancers Advocacy Groups 
ESGO: European Society of Gynaecological Oncology 
EU : European Union 
HPV: human papillomavirus 
IARC: International Agency for Research on Cancer 
WHO: World Health Organisation 
 
2 
post print  
ABSTRACT 
The age-standardised incidence of cervical cancer in Europe varies widely (between 3 and 
25/100 000 women-years) in 2018. HPV vaccine coverage is low in countries with the 
highest incidence and screening performance is heterogeneous among European countries. A 
broad group of delegates of scientific professional societies and cancer organisations endorse 
the principles of the WHO call to eliminate cervical cancer as a public health problem, also in 
Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage 
among girls by the age of 15 years and also boys, if cost-effective; they should introduce 
organised population-based HPV-based screening and achieve 70% of screening coverage in 
the target age group, providing also HPV testing on self-samples for non- or under-screened 
women; and to manage 90% of screen-positive women. To guide member states, a group of 
scientific professional societies and cancer organisations engage to assist in the roll-out of a 
series of concerted evidence-based actions. European health authorities are requested to 
mandate a group of experts to develop the 3rd edition of European Guidelines for Quality 
Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening 
and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 
pandemic, having interrupted prevention activities temporarily, should not deviate 
stakeholders from this ambition. In the immediate post-epidemic phase, health professionals 
should focus on high-risk women and adhere to cost-effective policies including self-
sampling.    
 
Key words: cervical cancer screening, HPV vaccination, Europe, WHO, elimination of 
cervical cancer, COVID-19.  
 
 
Novelty and impact 
This reports addresses for the first time the question how Europe could answer to the 
ambitious call from the World Health Organisation to reduce the incidence of cervical cancer 
to less than 4/100 000/year by reaching, by the year 2030  ≥90, 70 and 90% coverage for 
HPV vaccination, HPV-based screening and management of screen-positive women, 
respectively.  The occurrence of the COVID-19 pandemic, having interrupted prevention 
activities temporarily, should not deviate stakeholders from this ambition. 
 
 
Current burden of cervical cancer 
According to the International Agency for Research on Cancer (IARC) estimates of the 
cancer burden in Europe, approximately 33,000 women were diagnosed with cervical cancer 
and 15,000 died from the disease in 20181. These estimates concern the European region as 
defined by the United Nations. The incidence rates vary widely within Europe, with age-
standardised incidence rates (ASIR) ranging from less than 5/100,000 in Malta (3.5), 
Switzerland (3.8), Finland (4.7) to ASIRs over 20/100,000 in Latvia (25.0), Bosnia 
Herzegovina (23.9), Estonia (22.5), Moldova (21.4), Serbia (20.3) and Bulgaria (20.3) (see 
Figure 1 and Table 1).   
There is a clear Western to Eastern Europe trend with ASIRs lower than 10/100,000 and age-
standardised mortality rates (ASMR) lower than 3/100,000 in Northern, Southern and 
Western Europe, compared with ASIR of 16/100,000 and ASMR of 6/100,000 in Central-
Eastern Europe. In the 28 member states of the European Union (as defined in 2018, still 
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including the UK), the average age-standardised incidence and mortality rates are 10.0 and 
3.1 per 100,000 women-years, respectively.  For a more detailed assessment of the burden of 
cervical cancer in Europe versus other continents and on the methodology of estimation, we 
refer to a recent publication in Lancet Global Health1 and the description of the sources and 
methods used in developing the GLOBOCAN estimates2,3. 
 
Prevention of cervical cancer 
Historically, screening by detection and treatment of cervical pre-cancer lesions identified 
through cytological examination of Pap smears has resulted in a significant reduction in 
cervical cancer incidence and mortality4-6.  The implementation of the European Guidelines 
for Quality Assurance of Cervical Cancer Screening has played a pivotal role in achieving 
this result7. However, recent trend analyses indicate that even in countries with well-
organised cytology-based screening programmes, cervical cancer incidence rates have 
stopped decreasing or are even increasing1,8-10.  This phenomenon might be explained by an 
increased exposure to oncogenic types of the human papillomavirus (HPV), lower screening 
coverage rates, particularly amongst young women, and the limitations of cytology-based 
screening1.  
Therefore, new effective preventive tools, that have become available in the last decade, 
should be implemented without delay.  
Strong evidence has accumulated, indicating that primary prevention by vaccination against 
the main carcinogenic HPV types is safe and protects well against future HPV infection and 
associated ano-genital precancer in young females and males11-15. However, current HPV 
vaccine coverage estimates show very large discrepancies among countries (Table 2).  The 
ECDC in its recently released guidance on HPV vaccination in EU countries stated that a 
gender neutral vaccination becomes increasingly cost-effective in presence of persistently 
sub-optimal coverage of females with reducing vaccine price16.  However, in countries with 
HPV vaccination coverage of 80% or higher among girls, boys are already well protected by 
herd-immunity, which renders gender-neutral vaccination less cost-effective. Interventions to 
increase vaccination coverage among girls where it is low, might be more cost-effective than 
adding vaccination of boys17.  Intervention research aiming to identify effective strategies to 
increase HPV vaccination uptake and implementation of such strategies should be promoted. 
Regarding secondary prevention, randomised population-based trials have demonstrated that 
HPV-based screening is more performant in protecting against incident cervical precancer 
and cancer than cytology18,19. In addition, screening with validated polymerase chain reaction 
(PCR)-based HPV assays offers the advantage that it can be performed on a specimen 
collected by the woman herself. The offer of self-sampling devices has been shown to be 
performant in reaching under-screened populations20,21. Neither the WHO, nor EU guidelines, 
recommend screening by co-testing with HPV and cytology22,23.  
HPV infection is mainly sexually transmitted and this fact entails sensitive and tailored 
communications, including appropriate health education, to the general public as well as to 
individual women needing counselling in order to reduce stigma, shame and worry, by taking 
into account the particular social, cultural and background24,25. 
 
WHO call for the elimination of cervical cancer 
Recognising that cervical cancer affects many women at an age when they have important 
economic and familial responsibilities and acknowledging its high level of preventability, has 
motivated the WHO Director General to launch an appeal to all countries of the world to 
eliminate this disease as a public health problem26. It is estimated that by vaccinating 90% of 
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girls before they reach the age of 15 years, by screening 70% of women at least twice in the 
age-range 30-40 years, and by treating at least 90% of screen-detected cervical pre-cancer 
lesions, by 2030, the incidence of cervical cancer could be reduced to the level of a very rare 
disease (≤4 per 100,000/year) by the end of the current century22,27.  European countries 
(most of which belong to the group with very high human development index [HDI]) could 
reach this goal sooner, by 2055–5927.   
 
Proposal for European actions 
Implementation of HPV-based screening as recommended in EU guidelines, including 
offering non-screened women the choice of self-sampling, in combination with HPV 
vaccination of girls, and vaccination of boys if resources permit, could achieve the WHO goal 
in European countries by 2050-2065 depending on the current burden and the chosen 
strategies (see red line in Figure 1)27.  On the initiative of the European CanCer Organisation 
(ECCO) and the European Society of Gynaecological Oncology (ESGO), a resolution was 
adopted proposing as series of goals and actions to be taken to support the achievement of the 
WHO goal in Europe (https://www.eccosummit.eu/Resolutions/HPV, see Text boxes 1-5).  
The following organisations have endorsed this proposal for European actions; ESGO, ECCO 
and EFC. Upon the initiative of ESGO, the resolution was widened to a platform of experts 
and representatives from other involved societies, and cancer institutions and agencies. 
 
The series of actions enumerated above contributing to the elimination of cervical cancer 
were compiled before the outbreak of the COVID-19 pandemic. The control measures against 
the spread of SARS-coV-2 have interrupted the implementation of current preventive 
programmes and delayed new activities planned in Europe and elsewhere28. Concerns related 
to cervical cancer control amidst the COVID-19 pandemic and the period thereafter are 
addressed in Text Box 6.   
 
Conclusions 
Previous editions of the European Guidelines for Quality Assurance in Cervical Cancer 
Screening, mandated by the European Commission, were pivotal in introducing the 
implementation of organised secondary prevention of this malignancy in EU member 
states23,29. Today, new generations of vaccinated women are entering the target age group for 
screening and this new situation requires updated guidance.  The authors of this paper 
underline the need for a new third edition of EU guidelines for integrated primary and 
secondary prevention of cervical cancer. Whilst waiting for an official mandate from the EU 
Commission, a large group of professional societies and cancer organisations are engaged 
and willing to assist the WHO and European health authorities to achieve the laudable goal of 
eliminating cervical cancer.   
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Textbox, Figure and Table legends 
 
Text box 1. Action on HPV vaccination. 
 
Text box 2. Actions on HPV vaccination and screening. 
 
Text box 3.  Actions on screening and early diagnosis. 
 
Text box 4.  Actions on treatment. 
 
Text box 5.  Other actions to support the elimination goal. 
 
Text box 6. Limiting the impact the COVID-19 pandemic on cervical cancer prevention activities. 
 
 
Figure 1. World-age-standardised rates of incidence of and mortality from cervical cancer (/100,000 
women-years), in Europe, estimates for 2018, by country and ranked in descending order of 
incidence. The red line corresponds with the WHO Elimination target (4/100,000/year). 
(Source: IARC GLOBOCAN)1. 
 
Table 1. Burden of cervical cancer in the member states of the European Union, in 2018 (Source: 
IARC GLOBOCAN)1. 
 
Table 2. Estimations for 2018 of the vaccine coverage in European HPV vaccination programmes 
(aggregated by country). 
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Text box 1.  
• All European country cancer plans should include actions towards achieving population-
based and HPV vaccination of girls, and also vaccination of boys if cost-effective. 
• Vaccination programmes against the HPV infection should be in place in all European 
countries. 
• The target vaccination rate by 2030 in all European countries should be at least 90%, of 
adolescents preferentially for both genders, by the age of 15 years. 
• In support of vaccination goals, global cooperation should be fostered to resolve vaccine 
supply issues to ensure sufficient vaccine doses for the vaccination programmes of all 
countries. 
 
 
Text box 2.  
Guidelines on integrated HPV vaccination and cervical cancer screening should be regularly 
updated. A third edition of evidence-based EU Guidelines for Quality Assurance in Cervical 
Cancer Prevention should be developed, which should include recommendations on how to 
screen vaccinated populations. 
 
 
Text box 3.   
• By 2030, at least 70% of women in Europe, belonging to the target age group, should have 
been screened for cervical cancer with a clinically validated HPV test within the last 5 
years. This coverage should be reached as part of an organised programme. HPV screening 
programmes should take into consideration innovations such as self-sampling in order to 
reach women who may not participate in the regular screening programme. 
• Future European guidelines should include recommendations on how to communicate the 
results of HPV testing and how to counsel women and their partners to avoid stigma and 
shame. 
 
 
Text box 4.   
• Across all European countries, 90% of women with grade 3 cervical intraepithelial 
neoplasia should be treated within 3 months.  All women with diagnosed cervical cancer 
should have access to appropriate oncological services including palliative care for 
incurable cases. 
• All European country cancer plans should include actions towards achieving these 
treatment goals. 
• Guidelines on HPV vaccination and cervical cancer screening should also review the 
relevance of ablation (cryotherapy, thermal ablation) as a simple, safe and efficacious 
technique to treat cervical precancers, especially in younger women in Europe 
 
 
Text box 5.   
HPV awareness 
All European country cancer plans should include actions towards increasing public, patient 
and healthcare professional understanding and awareness of HPV. This awareness should 
include the range of HPV-related cancers and diseases, their symptoms and forms of 
prevention. Furthermore, this communication effort should elaborate to the public, patients and 
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healthcare professionals on the strategies being pursued to achieve the goal of cervical cancer 
elimination, and the role of the public, patients and healthcare professionals play in achieving 
the elimination goal. Awareness levels of the public, patients and healthcare professionals on 
HPV should be monitored and enhanced where necessary. 
 
Public confidence in HPV vaccination and actions against fake news 
• Health authorities and stakeholders should invest in effective communication about 
effectiveness and safety of HPV vaccines to generate a basis for confidence.    
• Cancer societies, patient and healthcare professional associations, and other stakeholders, 
should publish recommendations to combat the impacts on HPV vaccination uptake posed 
by deliberate misinformation spread via traditional news media (print and broadcast) 
or social media on ineffectiveness or risks associated with HPV vaccination. 
• All major social media platforms operating in Europe should have developed and 
implemented strategies to improve health literacy and reduce the spread of fake news on 
vaccination. 
• All national cancer plans in Europe should include actions to combat the deterrence effects 
of fake news upon HPV vaccination rates, as part of a broader campaign to reduce the 
negative impact of vaccination hesitancy on all vaccination programmes. 
 
Improving data and monitoring  
• By 2025, all European countries should have population-based registries in place to track 
and report upon HPV vaccination, HPV screening and cancer incidence and mortality data. 
• Monitoring should include reporting of harms associated with HPV vaccinations, screening 
and treatment of screen detected lesions. 
• European countries should evaluate cervical cancer screening programmes using the key 
performance indicators harmonized through the second European Screening Report (2017) 
and such evaluation reports should be published. 
 
Training 
Health professionals (general practitioners, nurses, specialists, care givers and field workers) 
involved in education, cervical cancer prevention, and treatment of pre-cancer should be aware of 
the principles of cervical cancer control and be adequately trained for their specific contributions. 
Training should include objective and tailored communication of the benefits and harms from 
primary and secondary prevention.    
 
EU Cancer Mission 
• The EU Cancer Mission should have clear elements within its programme that are 
supportive to the WHO global call for the elimination of cervical cancer as a public health 
problem. This should include supporting research priorities such as development and 
evaluation of new vaccine and screening technologies as well as care and treatment 
techniques. Research on interventions that optimise population coverage and adherence to 
follow-up, risk-based management as well as implementation science research focusing on 
transforming research findings to public health benefits should also be promoted. 
• EU Cancer Mission goals, such as on prevention and treatment of HPV-related disease, 
should be complemented by an EU Cancer Masterplan that supports achievement in respect 
to non-research related matters. This might include facilitating greater use of EU Structural 
Funds to achieve EU and WHO common goals pertaining to HPV vaccination, cervical 
cancer screening, treatment of screen-detected lesions, treatment of invasive cancer, as well 
as HPV awareness and education.  
 
Monitoring of EU Member State Cancer Plans 
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As part of the coordination role that the EU should play in assisting member states to combat 
cancer, a public monitoring and reporting system should be established in respect to EU member 
state cancer plan items, similar to ‘the State of Health in the EU’. This should include monitoring 
of actions towards international goals on HPV-related cancer elimination. 
 
 
Text box 6. Limiting the impact the COVID-19 pandemic on cervical cancer prevention activities 
European public health authorities, organisers of preventive health programmes, in general, and 
HPV vaccination and cervical cancer screening organisations, in particular, should safeguard 
allocation of resources and communicate clearly how prevention activities will resume after the 
control measures against the COVID-19 pandemic are relaxed.   
 
Given budgetary constraints, stakeholders and health professionals are invited to adhere strictly to 
evidence-based and cost-effective prevention policies.  Guidelines should be developed on safe 
collection of specimens, specimen handling, colposcopy, biopsy taking and treatment of precancer 
lesions in the immediate post-epidemic phase, prioritizing high-risk group30.  Offering self-
sampling kits might be anticipated. 
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Table1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASIR: age-standardised incidence rate (cases of cervical cancer per 100,000 women/year); 
ASMR: age-standardised mortality rate (deaths from cervical cancer per 100,000 women/year); 
computed by using the standard world population as reference; EU: European Union; UK: United 
Kingdom.   
*UK still was member of the EU in 2018. 
Member state  Nb cases  ASIR  Nb deaths  ASMR 
Austria          390  5.5            163  1.7 
Belgium          640  7.8            235  2.0 
Bulgaria       1,080  20.3            475  7.4 
Croatia          266  7.9            175  3.7 
Cyprus            45  5.7             18  1.5 
Czech Republic          813  9.9            435  4.0 
Denmark          415  10.9            131  2.0 
Estonia          230  22.5             60  4.3 
Finland          182  4.7             64  0.9 
France       3,067  6.7         1,472  2.3 
Germany       4,608  7.5         2,011  2.2 
Greece          696  8.1            271  2.1 
Hungary       1,312  17.2            499  5.1 
Ireland          340  11.0            107  2.9 
Italy       3,105  7.1            986  1.5 
Latvia          339  25.0            134  6.5 
Lithuania          431  18.9            209  7.2 
Luxembourg            25  5.6             11  2.0 
Malta            11  3.5               7  1.4 
Poland       3,220  9.4         1,947  4.9 
Portugal          750  8.9            340  2.8 
Romania       3,308  19.5         1,743  8.9 
Slovakia          692  16.6            281  5.7 
Slovenia          110  7.1             65  2.8 
Spain       1,942  5.2            825  1.7 
Sweden          558  9.0            222  2.0 
The Netherlands          670  5.7            250  1.4 
UK*       3,430  8.4         1,033  1.7 
Whole EU     32,675  10.0       14,169  3.1 
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Table 2. 
28 member countries of the EU* 
Country Coverage Comment 
Austria - Estimate not available. No data reported 
Belgium 67% Estimate extrapolated from 2016. Estimate based on weighted 
average of survey data from regions (Flanders 89.5% and 
Wallonia-Brussels 36.1%) 
Bulgaria 5% 
 
Croatia - Estimate not available. No data reported 
Cyprus 64% Estimations for the Government Controlled Area. 
Czech Republic - Estimate not available. No data reported 
Denmark 54% 
 
Estonia 44% 
 
Finland 62% Estimate based on reported coverage from the national 
vaccination registry. 
France 24% 
 
Germany 31% Data not reported. Estimate extrapolated from 2017 
Greece - Estimate not available. No data reported 
Hungary 71% 
 
Ireland 62% 
 
Italy 40% 
 
Latvia 53% 
 
Lithuania 46% 
 
Luxembourg 14% Estimate extrapolated from 2015 
Malta 81% 
 
Netherlands 45% Estimate based on reported coverage data for the 14th year 
cohort from the national vaccination registry. 
Portugal 80% Estimate based on reported official coverage. 
Romania - HPV vaccination not introduced 
Slovakia - HPV vaccination not introduced 
Slovenia 45% 
 
Spain 69% 
 
Sweden 75% Estimate based on reported official coverage. 
UK* 81%  
* In 2018, the UK still was member of the European Union. 
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Table 2 (continued). 
Other European countries 
 
Country Coverage Comment 
Andorra - Estimate not available. No data reported 
Armenia 2% 
 
Azerbaijan - Vaccine not introduced 
Belarus - Vaccine not introduced 
Georgia - 
 
Iceland 85% 
 
Liechtenstein 
  
Moldova - Vaccine not introduced 
Macedonia 40% 
 
Monaco - Estimate not available. No data reported 
Norway 86% 
 
Russia - Vaccine not introduced. Only in some regions 
San Marino 16% 
 
Switzerland 57% Estimate based on national survey. Females who were 16 at the 
age of the interview. 
Ukraine - Vaccine not introduced 
 
Source: ICO WHO 2018 Estimates 
(http://www.who.int/immunization/monitoring_surveillance/data/HPV_estimates.xls) 
 
